Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality. Our most advanced experimental agent, AGX101, targets the intracellular transporter TM4SF1 to treat solid cancers, and is being evaluated in an ongoing clinical study. As an investigational agent, it has not yet been proven safe and effective.

Expanded access to experimental medicines, also known as compassionate use, is permitted by the U.S. Food and Drug Administration (FDA) for patients with serious diseases who have exhausted other treatment options and cannot participate in an ongoing clinical trial. For such patients, expanded access may allow access to investigational drugs.

At this time Angiex does not offer an expanded access program for our investigational drug and encourages eligible patients to consider enrolling in AGX101’s clinical trial. More information about Angiex clinical trials can be found on this website or at www.clinicaltrials.gov.

To learn more about expanded access, please visit the FDA’s web page: Expanded Access | Information for Patients.